What does this research mean for the field?

G-CSF administration during neoadjuvant chemotherapy can be associated with the development of aortic arteritis in patients with breast cancer. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To highlight the occurrence of aortitis following G-CSF administration during breast cancer chemotherapy.

March 16, 2026Open Access

A Case of G-CSF-Associated Aortitis during Neoadjuvant Chemotherapy for Breast Cancer

Puntos clave

To highlight the occurrence of aortitis following G-CSF administration during breast cancer chemotherapy.
Case report of a 62-year-old woman with HER2-positive breast cancer.
Patient received pegfilgrastim for febrile neutropenia prophylaxis.
Tracked symptoms and treatment response following G-CSF administration.
Patient developed fever and chest pain 11 days post-G-CSF administration.
Oral levofloxacin treatment did not alleviate the symptoms.
Emergency transportation to the hospital was required due to persisting symptoms.

Resumen

We report a case of aortic arteritis associated with granulocyte colony-stimulating factor (G-CSF) administration during neoadjuvant chemotherapy for breast cancer. The patient, a 62-year-old woman, underwent treatment for human epidermal growth factor receptor 2 (HER2)-positive left invasive ductal carcinoma. Eleven days after receiving pegfilgrastim (3.6 mg) for febrile neutropenia prophylaxis, she developed fever and chest pain. Despite a five-day course of oral levofloxacin, the symptoms persisted, prompting emergency transportation to our hospital.

Me gusta

Guardar

Ver artículo completo